Observational study on Effectivenessof micronized progesterone versus dydrogesterone in supporting high risk pregnancy

Introduction: High-risk pregnancies, increasingly prevalent, face complications like threatened miscarriage, often linked to progesterone deficiency. Supplementation with micronized progesterone or dydrogesterone aims to mitigate these risks. This study was designed to compare the effectiveness of dydrogesterone and micronized progesterone. Material and methods: This is observational study. Group I patients included those who were being administered micronized progesterone orally 200 mg twice daily whereas group II included those patients who were being administered orally dydrogesterone 10 mg twice daily. Patients were then followed up and their pregnancy outcome was also studied. Data for each group was collected till pregnancy outcome data of 75 patients of each group was completed. Results: Dydrogesterone demonstrated superior efficacy in preventing early abortion compared to micronized progesterone. Nausea and vomiting were observed significantly more in dydrogesterone administered group whereas constipation was observed just significantly more in Micronized Progesterone administered group and drowsiness and giddiness were reported only in Micronized Progesterone administered group. Perinatal mortality was significantly higher in the group treated by Micronized Progesterone. Conclusion: This study indicates dydrogesterone superiority in preventing early abortion in high-risk pregnancies. While both progestogens showed comparable effects on other outcomes, their side effect profiles differed. Dydrogesterone may be advantageous for early pregnancy support in women at risk of miscarriage. Individualized treatment considering patient factors and side effects is crucial.